Is Imbruvica a chemotherapy drug?
- Imbruvica is not a chemotherapy drug. It is a targeted treatment.
- Imbruvica works by inhibiting the enzyme Bruton tyrosine kinase (BTK), which is part of a crucial signaling pathway in certain cancers, especially B-cell leukemias and lymphomas.
- BTK plays an important role in the survival of cancer cells, telling them to grow and divide uncontrollably.
- By blocking this pathway Imbruvica triggers the death of cancer cells.
Imbruvica (ibrutinib) is a targeted medicine that works by inhibiting the enzyme Bruton tyrosine kinase (BTK), which is a key signalling molecule that plays a crucial role in the survival of certain cancers, especially B-cell leukemias and lymphomas.
By blocking BTK, Imbruvica blocks the signals that stimulate malignant cells to grow and divide out of control, triggering the death of cancerous cells.
Imbruvica may be used in the treatment of
- Waldenstrom's macroglobulinemia
- Chronic lymphocytic leukemia
- Small lymphocytic lymphoma.
Imbruvica may also be used to treat chronic graft-versus-host disease.
Related questions
- How long can you stay on Imbruvica (ibrutinib)?
- How much does Imbruvica cost?
- Can ibrutinib be stopped safely?
What is the difference between chemotherapy and targeted treatment?
Chemotherapy focuses primarily on the fact that cancer cells divide rapidly, so it kills rapidly dividing cells. Unfortunately, some of our normal cells divide rapidly too, which is why chemotherapy has multiple side effects, such as mouth problems, low blood counts, and hair loss.
Targeted treatment identifies other features of cancer cells that are different from normal cells, or are more overactive than normal cells. There are many different types of targeted treatment and each one works a bit differently, but they all interfere with the ability of the cancer cell to grow, divide, repair or communicate with other cells. Research continues to identify additional cancer features to target and work out which cancers are best treated with targeted therapies.
References
- Imbruvica (ibrutinib) capsules [Package Insert] Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc https://www.drugs.com/pro/imbruvica.html
Read next
How quickly does Imbruvica (ibrutinib) work?
In some people, very good partial clinical responses to Imbruvica may occur within three to six months. Imbruvica is usually given until disease progression or unacceptable toxicity occurs, or in the case of graft vs host disease, recurrence of an underlying malignancy. The average duration of Imbruvica therapy in clinical trials has been around 41 months (range, 2–51 months). Continue reading
Acalabrutinib vs. ibrutinib: How do they compare?
A 2021 phase III study in the Journal of Clinical Oncology found that while both medications have similar efficacy, acalabrutinib was better tolerated with fewer side effects. Continue reading
Does ibrutinib cause hair loss?
Hair loss (alopecia) has not been noted as a side effect of ibrutinib (Imbuvica) in the product label. Textural hair changes (softening, straightening or curliness) and nail changes (brittle fingernails and toenails) were noted in a study evaluating ibrutinib use over the long term for treatment of chronic lymphocytic leukemia (CLL). Continue reading
Related medical questions
- What are the names of the BTK inhibitors?
- Who makes Imbruvica?
- How to apply for and use the Imbruvica copay card?
- Prednisone: What are 12 Things You Should Know?
- What is the success rate of Keytruda?
- Is Velcade a type of chemotherapy?
- How long does Velcade stay in your body?
- What is the cost of Yescarta?
- How and where is Adcetris administered?
- Is Adcetris a chemotherapy drug?
- How long does it take for Xalkori to work?
- How to pronounce Xalkori?
- Who makes Leukeran, and where is it made?
- What cancers are treated with Xalkori?
- How is Yescarta administered?
- What type of drug is Yescarta (axicabtagene ciloleucel)?